UF Engineers Build First DNA-Guided CRISPR System, Hit Perfect Hepatitis C Detection

A team of biomedical engineers at the University of Florida has reported what they describe as the first DNA-guided CRISPR system, a redesign of the gene-editing platform that swaps the usual RNA guide for a stable DNA molecule. In a paper published in Nature Biotechnology, the Gainesville researchers report that their system detected hepatitis C virus in patient samples with 100% accuracy and identified other viral targets including HIV with high sensitivity, results that could reshape how infectious disease testing is performed in clinics and at the bedside.

The work was led by faculty in the Herbert Wertheim College of Engineering, with collaboration from the UF College of Medicine and the UF Health clinical laboratories. The team built the platform around a Cas enzyme that has been engineered to recognize and bind DNA guides rather than the RNA guides used in conventional CRISPR systems. The change addresses long-standing practical problems with RNA, which is fragile, expensive to manufacture at scale, and difficult to store outside refrigerated conditions.

For Florida, the development is the latest in a string of biomedical research milestones from the state's flagship public university. UF Health, which operates hospitals in Gainesville and Jacksonville, has made diagnostic research a strategic priority over the past decade, with significant investment in flow cytometry, mass spectrometry, and now CRISPR-based detection. The university's research administration positions the work as evidence that Florida can compete with established biomedical hubs in Boston, San Francisco, and Houston.

How DNA-Guided CRISPR Works

Conventional CRISPR systems, including the widely used CRISPR-Cas9 platform that became famous for its gene-editing applications, rely on a short RNA molecule called a guide RNA to direct the Cas enzyme to a specific location in a target DNA sequence. The RNA guide is essentially a complementary template that pairs with the target through Watson-Crick base pairing. When the match is correct, the Cas enzyme cuts the DNA at the target site.

The UF team engineered a Cas enzyme that accepts a DNA guide instead of an RNA guide. DNA is chemically more stable than RNA, with a longer shelf life and tolerance for higher temperatures and a broader range of buffer conditions. The change does not affect the underlying recognition principle, which still depends on complementary base pairing, but it does change the practical engineering of any diagnostic or research kit that uses the system.

The implications for manufacturing are significant. DNA oligonucleotides can be synthesized at lower cost than RNA equivalents and can be stored as dry powder at room temperature for extended periods. For diagnostic test kits intended for use in low-resource settings, that combination of cost and stability matters enormously. Conventional CRISPR-based diagnostic test kits have struggled to reach widespread adoption in part because of the cost and cold-chain requirements associated with RNA reagents.

The Hepatitis C Result

To demonstrate the platform, the UF team applied it to hepatitis C virus detection, a clinically important diagnostic challenge. Hepatitis C is a bloodborne viral infection that can cause chronic liver disease, cirrhosis, and liver cancer if left untreated. Modern antiviral therapy can cure the infection in most cases, but the World Health Organization estimates that millions of people worldwide remain undiagnosed and untreated, in part because reliable diagnostic testing is expensive and inaccessible in many settings.

The research team tested their DNA-guided system on patient samples and reported 100% accuracy across the tested cohort. The samples included confirmed hepatitis C-positive patients and confirmed-negative controls. The system correctly identified every positive sample and produced no false positives among the negative controls. The researchers acknowledge that larger validation studies will be required before clinical use, but they describe the initial results as exceeding their expectations.

The platform's sensitivity allows it to detect low viral loads, an important capability for both early infection screening and monitoring of treatment response. The team also reported strong performance on HIV detection in a separate set of experiments, suggesting that the system can be adapted to other targets with minimal redesign of the underlying biochemistry. Adapting the system to a new target typically requires only synthesis of a new DNA guide that matches the target sequence.

From Lab to Clinic

The path from a research publication to a clinically approved diagnostic test is rarely fast, and the UF team is candid about the steps ahead. The platform will need to undergo extensive validation in larger and more diverse patient cohorts, including samples from communities with different viral genotypes and from patients with co-infections. The U.S. Food and Drug Administration will require manufacturing process validation, clinical performance studies, and quality system controls before any device based on the technology could be marketed.

The university's commercialization office is working with the research team on intellectual property protection and potential licensing pathways. UF Innovate, the university's startup support arm, has previously helped spin out biomedical companies based on Gainesville research, including several diagnostic and therapeutic startups. A spin-out company is one likely vehicle for the technology, although licensing to an established diagnostic firm is also possible.

The clinical deployment scenarios the team envisions include point-of-care testing in primary care clinics, community health screening programs, and use in low-resource settings around the world. A diagnostic test that can be performed without refrigerated reagents, sophisticated equipment, or specialized laboratory staff would meaningfully expand access to hepatitis C and HIV screening, particularly in rural communities and in countries with limited laboratory infrastructure.

Why This Matters for Florida

Florida has unique stakes in infectious disease diagnostic innovation. The state has consistently ranked among the top jurisdictions in the United States for new HIV diagnoses, with significant concentration in Miami-Dade, Broward, and Duval counties. Hepatitis C prevalence is also elevated in several Florida communities, particularly among populations affected by the opioid crisis. Affordable, accessible testing tools are central to public health efforts in both disease categories.

The Florida Department of Health operates a network of county health departments that conducts routine infectious disease screening, and the agency has periodically piloted new diagnostic technologies. UF Health's research and clinical operations work closely with the state health department on disease surveillance and on screening programs. A homegrown diagnostic platform that scales affordably could find an early adoption pathway through Florida's public health system.

Florida's biomedical research enterprise has been growing for years, with significant investment from the state through programs including the State University System's preeminence designation, which directs additional funding to top-performing research universities. UF, the University of South Florida, Florida State University, and the University of Miami have all received preeminence designation, and the resulting research capacity has produced a steady flow of biomedical publications and patents.

The Broader CRISPR Landscape

CRISPR technology has progressed dramatically since its initial development. The original CRISPR-Cas9 system, the subject of the 2020 Nobel Prize in Chemistry awarded to Jennifer Doudna and Emmanuelle Charpentier, has been joined by Cas12, Cas13, and a growing family of related systems. Each variant has different properties, with some preferring DNA targets, others preferring RNA, and still others optimized for specific kinds of recognition or for diagnostic applications.

CRISPR-based diagnostics emerged as a distinct application around 2017, with platforms including SHERLOCK and DETECTR pioneering the use of CRISPR systems to detect viral and bacterial sequences. The COVID-19 pandemic accelerated work on these platforms, and several CRISPR-based tests received emergency use authorization. The UF DNA-guided platform is the latest in this trajectory and may represent a step change in manufacturability and stability for the next generation of CRISPR diagnostics.

The research community has also pursued CRISPR-based gene therapy applications, with treatments for sickle cell disease, beta thalassemia, and several other inherited conditions now approved or in late-stage trials. The DNA-guided platform described by the UF team is positioned primarily as a diagnostic technology rather than a therapeutic, although future work could extend the principles to therapeutic applications.

Local Reaction and Industry Interest

The publication has drawn attention from the broader biotech industry and from clinical laboratory operators interested in the cost and stability profile of the platform. UF Innovate has reported initial inquiries from potential commercial partners, though specific deal discussions are not being disclosed. Industry analysts who track the diagnostic sector have noted that the published 100% accuracy figure on hepatitis C, while based on a small cohort, is consistent with strong specificity and sensitivity for the underlying biochemistry.

Within Florida, the announcement has been celebrated by economic development officials who view biomedical innovation as a long-term diversification strategy for the state economy. The Florida Department of Commerce and regional development organizations in Gainesville and Alachua County have been working for years to support a growing biomedical cluster around UF, and the university's research has anchored that effort. Startups that have emerged from UF in recent years span diagnostic devices, therapeutic biotech, agricultural biotech, and digital health.

Faculty at UF say the work reflects a broader strategy of pursuing applied research with clear translation pathways. The university's Herbert Wertheim College of Engineering and its biomedical engineering department have grown rapidly over the past decade, hiring faculty whose work spans medical imaging, neural engineering, biomaterials, and now CRISPR diagnostics. The college's facilities include shared lab space for instrumentation, animal facilities, and a clean room used for nanofabrication.

What's Next

The UF team plans to expand the validation of the DNA-guided CRISPR platform across additional clinical samples and to develop adaptations for other high-priority infectious disease targets. Tuberculosis, syphilis, and several emerging viral threats are on the list of candidates. The team is also working to develop a portable detection device that pairs with the chemistry, with the goal of a hand-held reader that could be operated by community health workers with minimal training.

The Nature Biotechnology publication is expected to spark follow-up work in other research groups, which is common when a substantively new method is introduced. The CRISPR research community has shown a strong pattern of rapid replication and extension of new techniques, and the DNA-guided approach is likely to be tested in multiple labs within months.

Industry partnerships will be critical to translation. The team has indicated that conversations are underway with several diagnostic firms and with at least one major hospital network interested in piloting the technology for in-house lab use. Additional grant funding is expected to come from the National Institutes of Health, with potential support from the Bill and Melinda Gates Foundation and other global health donors who have long backed work on affordable infectious disease diagnostics. The Florida Department of Health has also signaled interest in tracking the technology's progress for potential public health applications within the state.

For UF, the publication adds another high-profile result to a growing portfolio of biomedical research, and for Florida residents, it raises the prospect that the next generation of affordable infectious disease tests could carry a label that reads Made in Gainesville. The university's research enterprise has been steadily climbing in national rankings, and faculty cite the open question of whether Florida can build a self-sustaining biomedical research ecosystem capable of competing for top talent and federal grants with established hubs elsewhere in the country. A high-profile result in Nature Biotechnology is the kind of marker that supports those ambitions.